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MrpL35, a mitospecific component of 
mitoribosomes, plays a key role in cytochrome 
c oxidase assembly
ABSTRACT Mitoribosomes perform the synthesis of the core components of the oxidative 
phosphorylation (OXPHOS) system encoded by the mitochondrial genome. We provide evi-
dence that MrpL35 (mL38), a mitospecific component of the yeast mitoribosomal central 
protuberance, assembles into a subcomplex with MrpL7 (uL5), Mrp7 (bL27), and MrpL36 
(bL31) and mitospecific proteins MrpL17 (mL46) and MrpL28 (mL40). We isolated respiratory 
defective mrpL35 mutant yeast strains, which do not display an overall inhibition in mitochon-
drial protein synthesis but rather have a problem in cytochrome c oxidase complex (COX) 
assembly. Our findings indicate that MrpL35, with its partner Mrp7, play a key role in coordi-
nating the synthesis of the Cox1 subunit with its assembly into the COX enzyme and in a 
manner that involves the Cox14 and Coa3 proteins. We propose that MrpL35 and Mrp7 are 
regulatory subunits of the mitoribosome acting to coordinate protein synthesis and OXPHOS 
assembly events and thus the bioenergetic capacity of the mitochondria.
INTRODUCTION
Mitochondrial ribosomes (mitoribosomes) perform the synthesis of 
a small, but important, subset of the mitochondrial proteome, which 
is encoded by the mitochondrial genome and represents key com-
ponents of the oxidative phosphorylation (OXPHOS) system (Borst 
and Grivell, 1978; O’Brien, 2003; Smits et al., 2007; Kehrein et al., 
2015; Greber and Ban, 2016; Ott et al., 2016; Mai et al., 2017). Thus 
the regulation and activity of mitoribosomes have a major potential 
impact on an organism’s capacity to generate its energy through 
aerobic respiration. Due to the endosymbiotic origin of mitochondria, 
the mitoribosomes are evolutionarily related to bacterial ribosomes 
and thus share a number of overlapping features, such as antibiotic 
sensitivities and similarities in protein subunit composition (O’Brien, 
2002, 2003; Gruschke et al., 2010; De Silva et al., 2015; Greber and 
Ban, 2016; Ott et al., 2016). Despite these similarities, mitoribo-
somes display important compositional and functional differences 
from their prokaryotic ancestors. Mitoribosomes contain a higher 
protein:rRNA ratio than bacterial ribosomes, and this extra protein 
content manifests itself in two ways. First, several of the evolution-
arily conserved mitoribosomal proteins are larger than their bacte-
rial counterparts, having acquired additional, extension sequences 
(often C-terminal) and being termed mitochondrial-specific or 
“mitospecific” sequences. Second, mitoribosomes contain a num-
ber of additional novel proteins, that is, mitospecific ribosomal pro-
teins, which are often conserved throughout eukaryotes but do not 
have counterparts in the prokaryotic ribosomes (Graack et al., 1988; 
Koc et al., 2000; O’Brien, 2002; van der Sluis et al., 2015). The sig-
nificant advances in the structural analysis of mitoribosomes, 
including from the yeast Saccharomyces cerevisiae, have greatly 
enhanced our knowledge of the location of these mitospecific 
elements within the mitoribosome structures (Amunts et al., 2014; 
Brown et al., 2014; Greber et al., 2014a,b, 2015; Kaushal et al., 
2014; Amunts et al., 2015; Kaushal et al., 2015; Desai et al., 2017). 
However, little is known about the function of these mitospecific 
protein features and how they may contribute to, or regulate, the 
translational process of the mitoribosome.
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Coa3(Cox25) proteins (Mick et al., 2010; Fontanesi et al., 2011; 
Clemente et al., 2013; McStay et al., 2013; Garcia-Villegas et al., 
2017). Limiting in levels, the Mss51 remains bound to the Cox1 
protein-Coa3 intermediate and thus unavailable to bind the COX1 
mRNA to promote further rounds of Cox1 synthesis, until the as-
sembly of Cox1 together with the nuclear encoded COX subunits 
proceeds. Further progression of Cox1 in its assembly pathway 
causes the release and recycling of Mss51, making it available to 
initiate the next round of Cox1 protein synthesis. The presence of 
Cox14 and Coa3 are required to trap Mss51 in the Cox1-assembly 
intermediate and they thus act as negative Cox1-translational regu-
lators (Mick et al., 2010, 2011; Fontanesi et al., 2011). It is currently 
unclear what molecular mechanism drives the subsequent recycling 
of Mss51 from this Cox1-intermediate and whether, and how, the 
Cox14 or Coa3 proteins may be directly involved.
In this present study, we have used the yeast model S. cerevisiae 
to investigate the functional relevance of the mitospecific ribosomal 
protein, MrpL35 (also known as mL38 using the standardized 
mitoribosomal protein nomenclature). Conserved throughout eu-
karyotes (where in higher eukaryotes is referred to as MrpL38), 
MrpL35 (mL38) is a component of the central protuberance region of 
the large (54S) mitoribosomal subunit, where its functional relevance 
is unknown. Our evidence indicates that MrpL35 (mL38) protein is 
coassembled into a subcomplex with two other mitochondrial-
specific ribosomal proteins, MrpL17 (mL46) and MrpL28 (mL40), and 
together with proteins that are homologues of bacterial ribosomal 
proteins, MrpL7 (uL5), Mrp7 (bL27), and MrpL36 (bL31), respectively. 
MrpL35/mL38 proteins contain a C-terminal domain that displays 
homology to members of the conserved phosphatidylethanolamine-
binding protein domain (PEBP) family. The PEBP family comprises a 
diverse group of proteins present in many organisms and whose 
functions have been linked to the regulation of key cell signaling 
pathways (Banfield et al., 1998; Bruun et al., 1998; Serre et al., 1998; 
Yousuf et al., 2014). Through mutational analysis of the PEBP-like 
domain, we demonstrate here that MrpL35 plays a key role in coor-
dinating the synthesis and assembly of the COX complex. Our find-
ings demonstrate a connection among MrpL35, Cox1 synthesis, and 
the COX assembly components, in particular Cox14 and Coa3, and 
thus illustrate a link between the mitochon-
drial translation apparatus and the down-
stream OXPHOS assembly chaperones.
RESULTS
Mutation of residue Y275 of MrpL35 
results in a temperature-sensitive 
phenotype
The S. cerevisiae yeast mrpL35 null mutant 
strain (ΔmrpL35) expressing the wild-type 
MrpL35 protein (from a plasmid-borne 
gene) exhibited the ability to grow on the 
nonfermentable carbon (glycerol) source, 
whereas the strain lacking MrpL35 (i.e., 
ΔmrpL35+empty plasmid) was completely 
unable to do so (Figure 2A). This result 
illustrates the essential nature of MrpL35 
for respiratory/OXPHOS-based growth. 
Through mL38 protein sequence align-
ments, we sought to identify highly con-
served residues present in the PEBP-like 
homology domain, located at the C-termi-
nal end of the MrpL35 (mL38) proteins. 
One of these residues was a conserved 
Compositional differences between the mitochondrial and bacte-
rial ribosomes are thought to reflect a divergence in function of the 
mitochondrial translational apparatus from the bacterial. The mito-
chondrial proteome, in contrast to the bacterial, is mosaic in origin. 
The proteins synthesized by mitoribosomes are destined to become 
components of oligomeric complexes coassembled with these im-
ported nuclear encoded partners, a process facilitated by OXPHOS 
complex-specific chaperone proteins. Thus there is a need for a close 
coordination between the activity of the mitochondrial translational 
apparatus and the components involved in the import and assembly 
of their cytosol-synthesized partners (Gruschke and Ott, 2010; De 
Silva et al., 2015; Kehrein et al., 2015; Ott et al., 2016).
The cytochrome c oxidase complex (COX), the terminal electron 
acceptor in the mitochondrial OXPHOS machinery, is an oligomeric 
enzyme complex composed of mitochondrial translation products 
(Cox1, Cox2, and Cox3) partnered with multiple nuclearly encoded 
ones, imported from the cytosol. The assembly of this complex is a 
multi-step, chaperone-facilitated process that involves the uniting of 
protein subunits from two origins and in a strict stoichiometric man-
ner. Cox1, with its metal centers (two hemes [a+a3] and one copper, 
CuB), forms a central aspect of the catalytic core of the COX com-
plex. The synthesis and assembly of Cox1 into the COX complex 
is tightly regulated, with the proposed purpose of minimizing 
accumulation of potentially reactive Cox1-assembly subcomplexes 
(Khalimonchuk et al., 2010; Mick et al., 2011; McStay et al., 2013; 
Dennerlein and Rehling, 2015; Mayorga et al., 2016; Richter-Denne-
rlein et al., 2016; Soto and Barrientos, 2016). In yeast, Cox1 synthesis 
by the mitoribosomes is under the strict feedback regulation from 
the downstream COX assembly process and directly involves the 
Mss51 protein (Figure 1). Mss51, a heme sensing protein, promotes 
the translation of Cox1 by binding to the 5′-UTR of the COX1 mRNA 
(Perez-Martinez et al., 2003; Barrientos et al., 2004; Pierrel et al., 
2007; Perez-Martinez et al., 2009; Fontanesi et al., 2010; Mick et al., 
2010; Fontanesi et al., 2011; Soto et al., 2012; Mayorga et al., 2016). 
The Mss51 protein can also interact with the newly synthesized 
Cox1 protein (via the C-terminal end of Cox1), as it is cotranslation-
ally inserted into the membrane, where it forms an Mss51-contain-
ing Cox1-assembly intermediate (COA) with the Cox14 and 
FIGURE 1: Overview of the Cox1 synthesis and assembly pathway. Cox1 is synthesized on 
mitoribosomes tethered to the inner membrane at the site of the cotranslation insertion 
machinery containing the Oxa1 protein. Synthesis of Cox1 is promoted on activation by the 
translational activators Mss51 (and Pet309, not depicted) by their binding to the 5′-UTR of the 
COX1 mRNA. Following insertion into the membrane, the newly synthesized Cox1 protein 
forms an assembly intermediate with COX-specific assembly factors, including Cox14 and Coa3, 
which support the recruitment of Mss51 and its binding to the C-terminal end of the Cox1 
protein. Further maturation of Cox1 (e.g., incorporation of heme) and assembly with nuclear 
encoded COX partner subunits, facilitated by specific chaperones, leads to the assembly of 
Cox1 into the active COX enzyme and promotes the release of Mss51, which in turn activates 
the next round of Cox1 synthesis. Abbreviations: IM, inner mitochondrial membrane; IMS, 
intermembrane space; Matrix, mitochondrial matrix space.
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derivatives, mrpL35Y275A and mrpL35Y275D, respectively, supported 
respiratory-based growth of the ΔmrpL35 mutant at 30°C but not 
at the elevated temperature of 37°C (Figure 2A). In contrast, the 
relatively conservative exchange of Y275 for another aromatic 
residue Phe(F) did not appear to impact MrpL35’s ability to sup-
port aerobic growth at both temperatures tested (Figure 2A). Thus 
we conclude that the highly conserved Y275 residue must play 
a critical structural/functional role in the MrpL35 protein that is 
compromised by mutation to a smaller, or negatively charged, 
residue.
Mutation of Y275 residue does not prevent mitoribosome 
translation
Using an in vivo radiolabeling approach in the presence of cyclo-
heximide (to block cytosolic protein synthesis), we initially investi-
gated if the translational capacity of the mitoribosome was inhibited 
in mrpL35Y275A and mrpL35Y275D mutants grown either at the permis-
sive and nonpermissive temperature. In S. cerevisiae, the mitoribo-
somes synthesize eight proteins, Var1 (a small ribosomal subunit 
component) and OXPHOS subunits, Cox1, Cox2, and Cox3 of the 
COX (core subunits of the COX enzyme), and cytochrome b (of the 
cytochrome bc1 enzyme) and F1Fo-ATP synthase subunits, Atp6, 
Atp8, and Atp9. Both mutant strains displayed normal capacity for 
mitochondrial protein synthesis at the permissive temperature, and 
they retained the ability to synthesize also at 37°C (Figure 3A). Thus 
we conclude that the lack of OXPHOS-based growth of the mrpL35 
mutants at 37°C is not due to an absence of mitoribosomal transla-
tion at the elevated temperature. An overall reduction in total trans-
lation levels, in particular for the mrpL35Y275D mutant, was observed 
at 37°C, however, and may indicate a role for MrpL35 in mediating 
efficient mitochondrial translation or simply that the mitochondria of 
these cells were bioenergetically compromised after the prolonged 
growth period at the nonpermissive temperature, thus indirectly 
affecting their capacity for the energy-driven process of translation. 
When analyzed in isolated mitochondria, where exogenously added 
energy (ATP, GTP, and OXPHOS substrate NADH) were supple-
mented, the mrpL35Y275D mitochondria displayed normal level of 
protein synthesis (Figure 4A).
Western blotting of the protein extracts from the cells grown at 
the different temperatures indicated that the COX subunits, Cox1, 
Cox2, and Cox3, were strongly reduced in the mrpL35Y275A and 
more so in the mrpL35Y275D mutant strains grown at the nonpermis-
sive temperature of 37°C (Figure 3B). Although the mrpL35 mutants 
display the capacity to synthesize these COX subunits at 37°C, their 
strongly reduced steady-state protein amounts are indicative of a 
possible COX assembly defect at elevated temperatures, which 
would promote turnover of the newly synthesized Cox1, Cox2, and 
Cox3 proteins. Control experiments demonstrated that the preexist-
ing COX complex assembled in the mutant at the permissive 
temperature did not display an enhanced proteolytic instability (i.e. 
relative to the wild-type control assayed in parallel) when shifted to 
37°C (Supplemental Figure S1). These results indicate that if assem-
bled at the permissive temperature, the COX complex in the mutant 
cells displays a similar resilience as that of the wild-type control 
when shifted to 37°C. We conclude therefore that the reduced 
levels of COX complex in the mrpL35 mutants when grown at 37°C 
is indicative of a compromised ability to initially assemble the COX 
enzyme when the mitoribosomal protein synthesis and assembly 
processes occur at the nonpermissive temperature.
Although somewhat reduced, the levels of cytochrome b and 
Atp9 (and of Qcr7 and Atp4, two proteins dependent on the pres-
ence of cytochrome b- and Atp9-containing complexes, respectively, 
Tyr(Y) residue, corresponding to Tyr(Y)275 of the MrpL35 protein 
from S. cerevisiae, present in all mL38 proteins analyzed, and lo-
cated on the periphery of the PEBP-like domain of MrpL35 and in 
a region of the protein that is adjacent to its neighboring protein 
Mrp7 (bL27) (Figure 2B). We targeted the Y275 residue (indicated 
in yellow in Figure 2B) for site-directed mutagenesis, initially 
changing it either to Ala(A) or Asp(D). Expression of the resulting 
FIGURE 2: Mutation of residue Y275 of MrpL35 can result in a 
respiratory deficient phenotype. (A) Serial 10-fold dilutions of ΔmrpL35 
strain harboring a pRS413 plasmid containing gene inserts encoding 
either the wild-type MrpL35 protein (MrpL35WT), no insert (-) or genes 
encoding the mutated mrpL35 derivatives (mrpL35Y275A, mrpL35Y275D, 
or mrpL35Y275F), as indicated, were spotted on YP plates containing 
glucose (YPD) (2 d) or glycerol (YPG) (3 d) and grown at 30° and 37°C. 
(B) The images of MrpL35 (in red) and Mrp7 (in slate blue) structures 
were generated using PDB ID:5MRC. The position of the Y275 residue 
in MrpL35 targeted for mutagenesis is indicated in yellow.
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mitochondria, however, displayed an altered translation profile with 
the levels of Cox1, cytochrome b, and Atp6 elevated, relative to the 
wild-type control, and the levels of Cox2 were somewhat reduced 
(Figure 4A, left panel). The enhanced levels of newly synthesized 
Cox1 protein in the mrpL35 mutant mitochondria, in particular in the 
mrpL35Y275D mutant, indicated that the tightly regulated Cox1 synthe-
sis pathway may be misregulated (Figure 4A, right panels).
Western blotting of the isolated mrpL35 mutant mitochondrial 
preparations showed that the steady-state amounts of COX sub-
units Cox1, Cox2, and Cox3 were reduced, in particular in the 
mrpL35Y275D mitochondria, indicating that although synthesized at 
relatively normal (Cox2 and Cox3) or elevated (Cox1) levels in or-
ganello, the COX subunits fail to efficiently assemble in the mrpL35 
mutant (Figure 4B). Blue native gel electrophoresis (BN–PAGE) anal-
ysis of the individual OXPHOS complexes confirmed that the levels 
of assembled COX complex were strongly reduced in the mrpL35 
mutant mitochondria relative to the other OXPHOS complexes ana-
lyzed (Figure 4C, upper and lower panels). A parallel reduction in 
the level of COX enzyme activity was also measured in the mrpL35 
mutants (Figure 4D). In contrast, the levels of the cytochrome bc1 
and F1Fo-ATP synthase complexes, as indicated by steady-state 
analysis of individual subunits, BN–PAGE analysis of the complexes 
and their levels and assembly states, and the measurement of the 
cytochrome bc1 enzyme activity were not affected to the same ex-
tent as the COX complex was in the mrpL35Y275A and mrpL35Y275D 
mitochondria (Figure 4, B–D).
The ability of the mrpL35Y275 mutants to continue to synthesize 
Cox1, and moreover at elevated levels relative to the wild-type 
MrpL35 control, was not anticipated given the COX complex as-
sembly defect observed in these mitochondria. As outlined earlier, 
synthesis of Cox1 by the mitoribosomes is under strict feedback 
regulation with its assembly into the COX complex (Figure 1). 
Hence, as previously reported, Cox1 synthesis is characteristically 
reduced in COX assembly mutants, for example, Δcox10 and 
Δcox18 mitochondria, where the steady-state levels of COX sub-
units are strongly reduced (Figure 4E). In contrast, the mrpL35Y275 
mutant, despite having strongly reduced COX subunit levels, not 
only retains the ability but also displays enhanced capacity to syn-
thesize the Cox1 protein (Figure 4E).
Taken together, these data demonstrate that mutation of the 
MrpL35 protein at residue Y275 does not cause an overall inhibition 
in mitochondrial protein translation but rather results in an altered 
translational profile and a notable misregulated Cox1 synthesis 
behavior and a COX assembly defect.
Mutation in the Y275 residue of MrpL35 reveals a 
mitoribosomal connection to the COX assembly 
chaperones, Coa3 and Cox14
The observed elevated levels of Cox1 synthesis in the absence of 
assembly of the COX complex suggests that the Mss51 feedback 
regulatory system may be perturbed in the mrpL35 mutant mito-
chondria. Analysis of the steady-state levels of Mss51, Cox14, Shy1, 
and Coa3 assembly factors indicated them to be present in the 
mrpL35 mutant mitochondria at amounts similar to the wild-type 
MrpL35 control (Figure 5A). Thus the aberrant Cox1 synthesis and/
or lack of efficient COX enzyme assembly observed in the mrpL35 
mutant mitochondria was not due to altered levels of these key COX 
regulatory/assembly factors.
Following insertion into the membrane, newly synthesized Cox1 
forms a COA assembly intermediate with Coa3 and other factors 
(including Cox14, Mss51, Coa1, and Coa2), which facilitates its 
subsequent assembly into the COX enzyme. We therefore tested 
for their stability), were clearly less affected in the mrpL35 mutants 
than the COX subunits were (Figure 3B).
The mrpL35 Y275 mutants display a cytochrome 
c oxidase defect
To analyze the OXPHOS defect in the mrpL35Y275A and mrpL35Y275D 
mutant strains in more depth, mitochondria were isolated from cul-
tures grown in galactose/lactate media at the permissive temperature 
of 30°C. First, in organello translation in the presence of [35S]methio-
nine was performed, where we observed that the overall translational 
capacity of the mitochondrial ribosomes was not adversely af-
fected in the mrpL35 mutants (Figure 4A). The mrpL35 Y275D mutant 
FIGURE 3: The mrpL35 mutants maintain the ability to translate 
even at nonpermissive temperature. (A) MrpL35 wild-type 
mrpL35Y275A and mrpL35Y275D mutant strains were grown on minimal 
media supplemented with galactose grown at either 30°C or 37°C for 
24 h, as indicated. Mitochondrial translation capacity was monitored 
in vivo for 10 min with [35S]methionine and in the presence of 
cycloheximide (200 ug/ml). Equivalent amounts of cells were 
reisolated and proteins extracted and analyzed by SDS–PAGE, 
Western blotting, and autoradiography. (B) The indicated strains were 
grown as described in A, total cellular proteins were extracted, and 
steady-state levels of indicated mitochondrial proteins were measured 
following SDS–PAGE, Western blotting, and immunedecorated with 
antibodies indicated. Tim17 served as loading control.
Volume 28 November 15, 2017 Mitoribosomal MrpL35 and COX assembly | 3493 
the affinity-purified Coa3His species from both the control and 
mrpL35 mutant mitochondria (Figure 5B). The observed association 
of Cox1 with Coa3His in the mrpL35Y275D mitochondria suggests that 
the COX assembly defect in this mutant is downstream of the Cox1 
synthesis and Coa3-Cox1 assembly intermediate formation events.
whether radiolabeled Cox1 in the mrpL35 mutants could be recov-
ered in a complex with Coa3, and to do so we employed MrpL35 
wild-type and mrpL35Y275D mutant mitochondria harboring a His-
tagged Coa3 derivative (Coa3His). Following in organello synthesis, 
radiolabeled Cox1 protein was recovered in a specific manner with 
FIGURE 4: The mrpL35 mutants are COX assembly defective and display an altered Cox1 synthesis profile. 
(A) Mitochondria were isolated from indicated strains, which had been grown at 30°C. Following a preincubation for 
10 min at 37°C, in organello labeling in the presence of [35S]methionine was performed for 20 min and 30 min, as 
indicated, followed by a chase for 5 min in the presence of puromycin and cold methionine. Mitochondria were 
reisolated and samples analyzed by SDS–PAGE, Western blotting, and autoradiography (left panel). The amounts of 
newly synthesized Cox1 were quantified by subsequent phosphorimaging and expressed as a ratio of the levels of Cox2 
and Cox3 synthesized in the same time period (30 min) (right panels). (B) Steady-state levels of the OXPHOS subunits in 
mitochondria (25, 50, 100 µg) isolated from indicated strains detailed in A were determined following SDS–PAGE, 
Western blotting, and immunedecoration. Tim44 was used as a loading control (upper panel). The amounts of Cox1, 
Qcr7, and Atp4 were quantified, normalized to Tim44 levels, and expressed as a percentage of the wild-type control 
(lower panels). (C) Mitochondria isolated from indicated strains were solubilized in DDM (0.6%) and subjected to BN–
PAGE analysis, Western blotting, and immunedecoration with antibodies against the cytochrome bc1 (bc1) subunit, 
cytochrome c1 (α−Cytc1), Cox3 (COX), and F1Fo-ATP synthase (F1Fo) subunits (α−F1α/β) (upper panels). The amounts of 
these complexes were quantified in the mutant mitochondria and expressed as a percentage of the control wild type 
(lower panels). (D) The specific activities of the cytochrome bc1 (top panel) and COX (bottom panel) enzymes were 
measured in the mrpL35 mutant and wild-type MrpL35WT control (WT) mitochondria, as described under Materials and 
Methods and expressed as a percentage of the wild-type control. Measurements were performed in triplicate and the 
statistical analysis and values were analyzed for statistical significance by Student’s t test. Data are presented as means ± 
SD of percentage of control. (E) In organello translation in the presence of [35S]methionine was performed for 30 min in 
the indicated mitochondria (upper panel) and further analyzed as described in A. The steady-state levels of indicated 
OXPHOS subunits were analyzed (lower panel), as described in B. Tim17 is used as a loading control.
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fraction of the protein recovered was present as a novel, slower mi-
grating species, termed here Cox14* (Figure 5C). A smaller propor-
tion of this novel Cox14* species (relative to mature Cox14 protein) 
was also observed in the Coa3His complex purified from wild-type 
MrpL35 control mitochondria. The enrichment of this novel Cox14* 
species with the Coa3-complex from the mrpL35Y275D mitochondria 
would indicate that the behavior of the Cox14 protein is altered 
when the function of the MrpL35 protein is compromised.
Affinity-purified Coa3His complexes were also analyzed to ascer-
tain whether the association of Coa3 with Mss51, Shy1, and Cox14 
was perturbed in the mrpL35 mutant (Figure 5C). Both Shy1 and 
Mss51 copurified with Coa3His; however, the levels of both proteins 
associated with the Coa3His complex from the mrpL35Y275D mito-
chondria were reduced, relative to those from the parallel wild-type 
control. Cox14 also detected in the affinity purified Coa3His com-
plex from the mrpL35Y275D mitochondria; however, a significant 
FIGURE 5: mrpL35 mutant exhibits alterations in Cox14 and Coa3 behavior. (A) Steady-state levels of proteins in 
isolated mrpL35 mutant mitochondria were determined as described in Figure 4B. (B) In organello translation in the 
presence [35S]methionine was performed for 30 min in isolated MrpL35WT or mrpL35Y275D mitochondria harboring 
Coa3His, or not, as indicated. Following translation, mitochondria were solubilized with 0.6% DDM and affinity 
purification of Coa3His on Ni-NTA beads was performed, followed by SDS–PAGE, Western blotting, and 
autoradiography (upper panel). The recovery of Coa3His on the Ni-NTA beads was demonstrated by immunedecoration 
of the resulting blot with anti-His antibody (lower panel). Total, 5% of solubilized material; Bound, 100% of affinity 
purified material recovered from the Ni-NTA beads. (C) Same as B, except the in organello step was omitted, 
mitochondria were solubilized in 1% digitonin, and immunedecoration with indicated antibodies was performed 
following Western blotting. The Cox14 and novel, slower migrating Cox14* species enriched with the affinity purified 
Coa3His complex is indicated. (D) BN–PAGE analysis of Coa3-containing complexes following solubilization of indicated 
isolated mitochondria with 1% digitonin. Western blotting and immunedecoration with Coa3 antisera was performed 
and protein complex that nonspecifically reacts with the Coa3 antiserum is indicated by **. (E) Chemical cross-linking 
using DSG (+) or the mock treatment of solvent DMSO alone (-) was performed on mitochondria isolated from the 
indicated yeast strains. Following SDS–PAGE and Western blotting, decoration with Coa3- antisera was performed. 
Note the area encompassing the 14.4- to 25-kDa range of the gel is only shown (upper panel), as no Coa3-specific 
cross-link adducts were observed in the higher molecular mass range of the gel (not shown). The minus cross-linking 
(DMSO) control is only shown for the MrpL35WT sample, as this reflected the results for all other mitochondrial types 
analyzed, that is, the complete absence of any Coa3-immunereactive material in this molecular weight range. The 
positions of the Coa3 monomer (lower panel and lighter exposure) and the four DSG-Coa3 adducts observed (upper 
panel) are indicated. A protein (14 kDa) that nonspecifically reacts with the Coa3 antiserum and observed in the lower 
panel, is indicated by **.
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BN–PAGE analysis indicated that the assembly of Coa3-contain-
ing complexes was significantly affected in the mrpL35Y275D mutant 
mitochondria (Figure 5D). In the wild-type MrpL35 control mito-
chondria, Coa3 was recovered in COA complexes of ∼240–480 kDa 
in mass, which have been proposed to also include the Cox1–Coa3 
assembly intermediates of the COX complex (McStay et al., 2013; 
Mayorga et al., 2016). The level of these Coa3–COA complexes was 
strongly reduced in the mrpL35Y275D mutant mitochondria, indicat-
ing that despite the fact that newly synthesized Cox1 could associ-
ate with Coa3 (Figure 5B), the assembly state of the predominant 
Coa3–COA-containing complexes was strongly perturbed in this 
mutant. As the steady-state levels of the Coa3 protein were not re-
duced in the mrpL35Y275D mitochondria (Figure 5A), we conclude 
that the majority of the Coa3 protein in the mutant must be present 
in complexes smaller than 60 kDa under these conditions and thus 
not retained in the BN–PAGE gel. In contrast to the mrpL35Y275D 
mutant, the assembly state of the Coa3 complex did not appear to 
be affected in the mrpL35Y275A mutant mitochondria. As these mito-
chondria had both been isolated from cells grown at the permissive 
temperature, it appears that the phenotype of the mrpL35Y275D mu-
tant is more severe and penetrated into cells grown at 30°C, in con-
trast to the mrpL35Y275A mutant. Consistently reduced COX levels 
were observed in these isolated mrpL35Y275D mitochondria and to a 
lesser extent in the mrpL35Y275A mitochondria (Figure 4, B–D). The 
aberrant assembly state of Coa3 observed in the mrpL35Y275D 
mutant was not simply due to the absence of an assembled COX 
enzyme, as Coa3-containing COA complexes were detected in mi-
tochondria from the Δcox10 and Δcox18 COX assembly mutants, 
analyzed in parallel. The perturbed assembly of the Coa3–COA 
complexes in the mrpL35Y275D mutant mitochondria mirrored, how-
ever, that observed in the Δmss51 and wild-type/ρ0 mitochondria 
(Figure 5D). In contrast to these mitochondria where Cox1 synthesis 
is absent (Barrientos et al., 2004), the mrpL35Y275D mitochondria 
retain the capacity to synthesize Cox1 and form Cox1–Coa3 inter-
mediates. We conclude therefore that in the ribosomal mutant 
mrpL35Y275D, the further (or stable) assembly of Coa3–Cox1 into 
larger Coa3–COA complexes was perturbed.
Finally, the molecular environment of Coa3 in intact mrpL35 mu-
tant mitochondria was independently probed with the chemical 
cross-linking agent disuccinimidyl glutarate (DSG) (Figure 5E). In the 
wild-type MrpL35 control mitochondria, endogenous Coa3 (8 kDa) 
was observed to form three small adducts in the presence of DSG, 
which corresponded to Coa3 cross-linked to partners of ∼14, 12, 
and 8 kDa, respectively. A reduction in the formation of the smaller 
two of the Coa3-adducts, and a parallel acquisition of a novel fourth 
Coa3- adduct, corresponding to Coa3 cross-linked to an 11-kDa 
protein, was observed instead in the mrpL35Y275D mitochondria. The 
Coa3-adduct profile in the mrpL35Y275D mitochondria bore similari-
ties to that obtained in the Δmss51 and Δcox14 mutant mitochon-
dria, analyzed in parallel, where loss of the Coa3+12 kDa and 
Coa3+8 kDa adducts, and the gain of the novel Coa3+11 kDa ad-
duct, was observed (Figure 5E). The altered Coa3-adduct profile in 
these mitochondria may be indicative of their COX-assembly defec-
tive phenotype, as it was also observed in Δcox18 mitochondria and 
also in the ribosomal mutant mrp20ΔC mitochondria, which are de-
fective in mitochondrial translation and, consequently, COX assem-
bly. Although the identities of the Coa3 cross-linked partners in 
these adducts are unknown at this time, the observed altered Coa3 
cross-linking pattern in the mrpL35Y275D mitochondria is further evi-
dence of an aberrant Coa3 condition in this mitoribosomal mutant.
In summary, the molecular environment of Coa3, and the nature 
of the Cox14 species associated with it, is altered in the mrpL35 
mutant. These perturbations may impact the productive nature of 
the Cox1-assembly intermediate formed with the Coa3 and thus the 
further assembly of Cox1 into the COX enzyme.
Mutation of Y275 residue perturbs the close relationship of 
MrpL35 with Mrp7 protein
The cryo-EM structures of yeast mitoribosomes indicate MrpL35 
(mL38) to be a peripheral component of the central protuberance 
where it is embraced by mitospecific elements of the Mrp7 (bL27) 
protein. To gain more insight into MrpL35 and the possible effect 
of the Y275 mutation on its interactions with partner proteins, we 
affinity purified His-tagged wild-type and mutant MrpL35 deriva-
tives, which had been expressed in the ribosome assembly yeast 
mutant, mrp20ΔC (Kaur and Stuart, 2011). Stable assembly of the 
54S particles has been reported to be defective in this mrp20ΔC 
mutant, and instead ribosomal proteins can be purified in subas-
semblies or subcomplexes, enabling their compositional analysis 
(Kaur and Stuart, 2011). The affinity purified wild-type MrpL35His 
was recovered in a complex with other proteins, which were shown 
either through specific antibody decorations or mass spectrometry 
analysis (Supplemental Table S1) to include Mrp7 (bL27), MrpL36 
(bL31), and MrpL7 (uL5) and two mitospecific proteins, MrpL17 
(mL46) and MrpL28 (mL40) (Figure 6A). Western blotting with 
available antibodies against Mrp7 (bL27) and MrpL36 (bL31) con-
firmed their specificity of their association with MrpL35His, as they 
were not detected in the Mrp20 ribosomal exit pore subcomplex, 
purified parallel via MrpL25His (mL59), a known component of the 
Mrp20 exit pore subcomplex (Kaur and Stuart, 2011) (Figure 6, B 
and C). Reciprocal affinity purifications of MrpL7His, MrpL17His, and 
Mrp7His from the mrp20ΔC mutant strain also confirmed their spe-
cific association with Mrp7, MrpL36, and MrpL35 proteins (Figure 
6B). The ability of Mrp7 to be copurified with the His-tagged 
derivatives of mrpL35Y275A and mrpL35Y275D proteins was strongly 
reduced relative to the wild-type MrpL35His control (Figure 6C). 
The recovery of MrpL36 (bL31) in the mutant mrpL35 subcom-
plexes was also reduced, albeit not to the same extent as the Mrp7 
protein. These results indicate that the interaction of MrpL35 with 
Mrp7 (and possibly other components of the central protuberance 
subcomplex) is perturbed through the mutation of the Y275 
residue, such that it does not remain associated with the Y275 
mutated mrpL35 protein under these detergent solubilization and 
purification conditions.
Steady-state analysis of protein levels indicated that a reduction 
in Mrp7 levels was observed in the mrpL35Y275D mutant (Figure 6D, 
upper and lower panels). Mutation of the Y275 to Ala(A) residue did 
not greatly compromise the stability of the MrpL35 protein, though 
a decrease in MrpL35 steady-state levels was seen with the mrp-
L35Y275D mitochondria. In contrast to Mrp7, the levels of MrpL36, 
another central protuberance constituent, or other 54S particle pro-
teins, for example, Mrp20 and MrpL4, were relatively unaffected in 
the mrpL35 mitochondria (Figure 6D).
Taken together, we conclude that the MrpL35 can assemble into 
a central protuberance subcomplex with the MrpL36, Mrp7, MrpL7, 
MrpL17, and MrpL28 proteins and that the association with, and 
possibly stability of, Mrp7 is perturbed through the mutation of the 
Y275 residue in MrpL35.
DISCUSSION
Mitochondrial translation and the assembly of the OXPHOS com-
plexes are processes of critical importance to aerobic metabolism 
and cell viability. Mutation and impairment of mitoribosome ca-
pacity has been shown to be directly associated with a range of 
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pathophysiological neuromuscular conditions (Lightowlers et al., 
2014; De Silva et al., 2015). Investigating the molecular details of 
mitoribosome activity, regulation, and coupling of translation to 
the downstream OXPHOS assembly events is therefore critical for 
our understanding of normal and dysfunctional cellular metabo-
lism. MrpL35 (mL38) is a mitospecific component of the yeast mi-
toribosomal 54S particle. Located in the central protuberance re-
gion, aspects of MrpL35 and the mitospecific domain of its partner 
protein Mrp7 (bL27) form an externally exposed element of this 
region of the mitoribosome (Amunts et al., 2014; Desai et al., 
2017). Mutation of residue Tyr(Y)275 of the MrpL35 protein was 
found to compromise its ability to support aerobic growth and 
OXPHOS assembly, in particular at elevated temperatures, with 
the exchange for the negatively charged Asp(D) residue being 
more deleterious than Ala(A). Surprisingly, the molecular basis for 
the defective OXPHOS function in the mrpL35 mutants was not 
due to a primary inhibition in mitochondrial protein translation, 
but rather our OXPHOS complex analysis supports a pronounced 
COX assembly defect in these mrpL35 mutants. The consequences 
of the mrpL35 mutation for the assembly of the cytochrome bc1 or 
F1Fo-ATP synthase complexes, which both also contain mitoribo-
some synthesized subunits, were not as pronounced as they were 
for the COX complex assembly. As the mrpL35 mutants retained 
the capacity to synthesize the mitochondrially encoded COX sub-
units, the strong reduction in COX complex steady-state levels 
indicates that a defect may lie in a posttranslational step required 
for the assembly of the COX complex. Furthermore, the elevated 
levels of Cox1 synthesized in the mutants, despite their gross COX 
assembly defect, points to a breakdown in the Mss51/Cox14/
Coa3-dependent feedback loop used to negatively regulate Cox1 
synthesis under conditions when further assembly of Cox1 into a 
COX complex is perturbed.
Our data indicate that newly synthesized Cox1 can form the 
Cox1–Coa3-containing assembly intermediate in the mrpL35 
mutant, but the further progression of Cox1 assembly from this in-
termediate into the Coa3–COA intermediate complex, and thus 
subsequently to the fully assembled COX enzyme, are defective. 
Both Cox14 and Coa3 act as negative regulators of the Cox1 syn-
thesis regulatory pathway (Mick et al., 2010; Fontanesi et al., 2011). 
Thus the elevated levels of Cox1 synthesized in the mrpL35 may 
also be indicative of a breakdown in the function of the Cox14 and/
or Coa3 proteins. We observed the presence of a novel form of 
FIGURE 6: Mutation of MrpL35 perturbs the association with and 
stability of Mrp7. (A) Isolated mrp20ΔC mitochondria harboring 
His-tagged derivatives of wild-type MrpL35 or MrpL25, as indicated, 
were solubilized with 1.0% Triton X-100 and subjected to affinity 
purification protocol with Ni-NTA beads. The Ni-NTA purified material 
was further analyzed by SDS–PAGE and silver staining. The positions 
of proteins identified to copurify with the MrpL35His and MrpL25His 
proteins are indicated. Note Rim1 and Mam33 were found to copurify 
with both the MrpL35His and MrpL25His subcomplexes, which was 
confirmed by Western blotting (Rim1) and reciprocal Mam33His 
purification studies (not shown). M, molecular mass marker proteins 
(kDa) used for SDS–PAGE. (B) Affinity purification of His-tagged 
MrpL7, MrpL17, MrpL35, Mrp7, and mrp20ΔC derivatives from 
mrp20ΔC mitochondria was performed as described in A with the 
exception that following SDS–PAGE, Western blotting and 
immunedecoration with indicated specific antibodies was performed. 
Total, 5% of solubilized material; Bound, 100% of affinity purified 
material recovered from the Ni-NTA beads. (C) Affinity purification of 
His-tagged MrpL35WT, mrpL35Y275A, or mrpL35Y275D derivatives or 
MrpL25His from mrp20ΔC mitochondria was performed and analyzed 
as described in B. (D). The steady-state amounts of mitoribosomal 
proteins were determined by analyzing indicated mitochondria, as 
described in Figure 4B (upper panel). The amounts of Mrp7, MrpL35, 
and MrpL4 were quantified, normalized to Tim44, and expressed as a 
percentage of the wild-type control (lower panel).
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(and/or Mrp7) independent of the assembled ribosome (e.g., alone 
or in context of a central protuberance subcomplex) could do so. 
Furthermore, it is also possible that MrpL35 and/or components of 
the central protuberance may serve to recruit Mss51 to the ribo-
some and thus modulate its capacity to act as a Cox1 translational 
activator; however, we have not obtained data to support a Mss51-
MrpL35 (or Mrp7) interaction to date. Another possibility is that 
MrpL35, through its PEBP-like domain, serves to affect COX assem-
bly by recruiting a common anionic factor important for signaling 
between the ribosome and the Coa3-Cox14-Mss51 proteins and 
thereby to balance the Cox1 synthesis rate with the downstream 
chaperoned assembly events. Mutation of the Y275 residue may 
impair this ligand binding and thus promote more Cox1 synthesis in 
a manner that is uncoupled from the downstream assembly events. 
Finally, the mutation of the MrpL35 protein could also cause altera-
tions in the ribosomal structure/organization that affects the acces-
sibility of the newly synthesized Cox1 protein to the Mss51 protein 
following its insertion into the membrane. Mss51 binds to the ex-
treme C-terminal tail of the newly synthesized Cox1 protein, a step 
required to recruit the chaperone into the Cox1–Coa3 assembly in-
termediate (Shingu-Vazquez et al., 2010; Garcia-Villegas et al., 
2017). Factors that hinder the access to the C-terminal region of the 
newly synthesized Cox1 may influence the recruitment of Mss51 to 
the Cox1–Coa3 complex. Delayed recycling of the ribosome at the 
termination of translation and/or impaired disengaging of the ribo-
some from Oxa1, the membrane site of cotranslational insertion of 
proteins, may both prevent Mss51’s timely access to the C-tail of 
Cox1. Interestingly, yeast mutants deficient in the ribosome-recy-
cling factor (Rrf1), which promotes ribosomal subunit dissociation 
and recycling, display an OXPHOS assembly defect that was not 
caused by an inhibition in mitoribosomal translation per se (Ostojic 
et al., 2016). Rather, similarly to the mrpL35 mutants, the rrf1 mutant 
mitochondria displayed an altered profile of synthesis products, in-
cluding increased levels of newly synthesized Cox1, and reduction 
in COX complex assembly levels. However, in contrast to the 
mrpL35 mutants, the yeast rrf1 mutants also exhibit a strong impair-
ment in the assembly of the F1Fo–ATP synthesis complex, in addi-
tion to the observed COX assembly defect (Ostojic et al., 2016). The 
molecular defect underpinning the COX assembly deficiency in the 
mrpL35 Y275 mutant would thus appear to be different from that 
rrf1 mutant and ribosome recycling where a more pleiotropic 
OXPHOS assembly defect is described. Taking this together with 
other mrpL35 results reported here, namely i) the maintained ability 
to form the Cox1-Coa3 intermediate, ii) the enrichment of Cox14* 
with Coa3, and iii) the altered assembly state of the Coa3 complex 
(as evidenced by chemical cross-linking and BN–PAGE approaches), 
we favor that the mrpL35Y275 mutation does not cause a general 
ribosome translation inhibition defect but rather has direct conse-
quences for functional integrity of the Mss51, Coa3, or Cox14 
proteins.
In summary, our findings here unexpectedly highlight that com-
ponents of the mitoribosome, MrpL35, and possibly its closely as-
sociated Mrp7 protein, play a role in regulating the COX assembly 
process, in particular by influencing the molecular environments of 
the Mss51, Coa3, and Cox14 proteins. Furthermore, this study also 
represents the first report of a novel Cox14 species, Cox14* associ-
ated with the Cox1–Coa3 complex, suggesting that Cox14 may be 
regulated by a posttranslational event. Future experimentation will 
ascertain the nature of the Cox14 modification and the role it plays 
in Cox14’s ability to support Coa3, Mss51, and the productive Cox1-
assembly pathway and how this may involve the mitoribosomes and 
MrpL35.
Cox14, the Cox14* species enriched with the purified Coa3 
complex and observed both in the wild type, and at greatly in-
creased proportions in Coa3 complexes from the mrpL35 mutant. 
The Cox14* species has not been reported in the literature to date 
and may represent a novel, post–translationally modified form of 
the Cox14 protein. The abundance of Cox14* with Coa3 complex 
in the mrpL35 mutant would indicate its recycling to its regular 
Cox14 status is perturbed in this mitoribosomal mutant, which in 
turn may stall the progression of Cox1–Coa3 assembly intermedi-
ate. Both BN–PAGE and chemical cross-linking data further illus-
trate that the stable assembly state of the Coa3–COA complexes is 
defective in the mrpL35Y275D mutant. Although the nature of this 
modification is currently unknown, we speculate here that the 
formation of Cox14*, and its possible recycling to Cox14, may influ-
ence the productive nature of the Cox1–Coa3 complex as an as-
sembly intermediate and/or its ability to recruit or retain Mss51 and 
thus Cox14’s ability to negatively control the Cox1 synthesis levels.
MrpL35, like the other members of the mL38 family, contains a 
PEBP-like domain in its C-terminal region. PEBP proteins are a 
highly diverse group of proteins (i.e., not exclusively mitoribo-
somal proteins) involved in signaling pathways. PEBP-domains 
form anion ligand-binding pockets, which can interfere with ki-
nase-based signaling pathways when they form complexes with 
anionic ligands (Banfield et al., 1998; Banfield and Brady, 2000; 
Yousuf et al., 2014). The cryoEM structural analyses of mitoribo-
somes indicates that the PEBP-region of MrpL35/mL38 proteins is 
exposed to an exterior surface of the CP (Amunts et al., 2014, 
2015; Greber et al., 2015; Desai et al., 2017). This aspect of the 
MrpL35 may represent a binding site for an external regulatory li-
gand or feature of a nonribosomal protein (e.g., a phosphorylated 
residue) in the central protuberance of the mitoribosome. Residue 
Y275 is conserved in all MrpL35 (mL38) proteins and is located in 
the PEBP-like domain of MrpL35 (mL38). It is unclear whether the 
PEBP-like domain of MrpL35 binds anionic ligands, but the con-
served nature of this domain, and the detrimental effect of the 
Y275 mutation, may suggest a role for MrpL35 in a signaling path-
way involving the mitoribosome. It is important to note that the 
region of MrpL35 where residue Y275 is located is directly adja-
cent to the fungal-specific, mitospecific domain of Mrp7 (bL27), 
which embraces the PEBP-like domain of MrpL35 (Amunts et al., 
2014; Desai et al., 2017). We observed that mutation of residue 
Y275 destabilized the association of MrpL35 with its partner 
protein Mrp7 and led to a reduction in Mrp7 levels in the mutant 
mitochondria. Some of the reported phenotypes in the mrpL35 
mutants could therefore be attributed to a disturbance in the rela-
tionship of MrpL35 with Mrp7 protein rather than (or in addition to) 
a defect in MrpL35.
How does mutation of MrpL35, a mitoribosomal protein of the 
central protuberance, affect the COX assembly pathway and at the 
level of the Coa3/Cox14 proteins? One possibility is a physical con-
nection between elements of the central protuberance, involving 
the PEBP-domain of MrpL35 and/or Mrp7, and the COX assembly 
chaperones, such as Cox14 and Coa3 proteins in the membrane, 
which is important for the correct operation of the COX assembly 
chaperones. The mitoribosomes are physically tethered to the inner 
membrane; however, to date this association has been shown to 
involve aspects of the 54S particle in the vicinity of the polypeptide 
exit channel and thus distanced from the central protuberance 
region (Jia et al., 2009; Gruschke et al., 2010; Haque et al., 2010; 
Pfeffer et al., 2015). It is therefore unlikely that MrpL35 in context of 
the translating ribosome can have a direct physical connection to 
the Cox14/Coa3 proteins; however, we cannot rule out that MrpL35 
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Miscellaneous
All experiments presented were performed at least three times; 
results were consistently reproducible, and representative examples 
of data are given in the figures. Spectral measurements of specific 
enzyme activities of the cytochrome bc1 and COX complexes were 
performed as previously described (Tzagoloff et al., 1975). In organ-
ello translation with [35S]methionine and chemical cross-linking with 
DSG (7.7 Å, homobifunctional, amine-specific), were performed as 
previously described (Hell et al., 2001). Mitochondrial isolation, 
protein determination, and SDS–PAGE were performed as previ-
ously described (Dienhart and Stuart, 2008). The Cox1 and Cox3 
antibodies used in this study were commercially obtained (Cox1: 
Molecular Probes, anti-yeast Cox1, mouse monoclonal 11D8-B7, 
lot# 6251-1; Cox3: Invitrogen/Novex Anti-Cox3 monoclonal, 
459300, lot#H3578). All other antibodies used were rabbit poly-
clonal against the respective purified yeast proteins and generated 
either in the Stuart lab or received as gifts (see Acknowledgments). 
Antigen–antibody complexes were detected by horseradish peroxi-
dase–coupled secondary antibodies and chemiluminescence de-
tection on x-ray films. Resulting signals were quantified following 
scanning using Image Studio software.
MATERIALS AND METHODS
Yeast strains and growth conditions
All S. cerevisiae strains used in this study are in the haploid W303-1A 
genetic background (W303-1A, mat a leu2, trp1, ura3, his3, ade2). 
They include the ΔmrpL35 (MRPL35::KAN) mutant and those har-
boring plasmid borne copies of the wild-type MRPL35 gene or 
mrpL35 mutant derivatives, created through a plasmid shuffling ap-
proach, as described below. The W303-1A-based strain mrp20ΔC + 
GAL10-mrp20ΔC (termed here mrp20ΔC) was also employed (Kaur 
and Stuart, 2011). Yeast strains were cultured using standard proto-
cols on either minimal medium supplemented as appropriate with 
uracil, tryptophan, leucine, adenine, histidine, or on full YP media, as 
indicated. Mitochondria were isolated from cultures grown at 30°C 
in minimal medium and containing 0.5% lactate and 2% galactose 
as carbon sources.
Generation of mrpL35 mutants
The yeast chromosomal MRPL35 open reading frame (ORF) was 
replaced with the KAN cassette in a haploid W303-1A yeast 
strain harboring a wild-type MRPL35 (MRPL35WT) genomic insert 
(corresponding to the MRPL35 ORF plus 650 base pairs 5′ and 
300 base pairs 3′) cloned into a pRS316 URA3-based plasmid. 
The resulting strain then transformed with the centromeric plas-
mid pRS413 (HIS3) harboring either a similar genomic fragment 
containing the wild-type or mutant mrpL35 derivative or no insert 
(i.e., the empty plasmid). Following plasmid shuffling process, 
involving growth on 5′FOA to promote the loss of the 
pRS316(URA3)-MRPL35WT plasmid, ΔmrpL35 transformants har-
boring only the pRS413(HIS3) plasmids were selected. The result-
ing strains (ΔmrpL35+MRPL35WT or ΔmrpL35+mrpL35Y275 deriva-
tives) are referred to here as the ΔmrpL35 null or MrpL35WT 
(wild-type) and the mrpL35Y275A, mrpL35Y275D, or mrpL35Y275F 
mutant strains. Mutations in the Y275 residue of MRPL35 gene in 
the pRS413(HIS3)-MRPL35 plasmid were generated using a PCR 
site-directed mutagenesis strategy.
Generation of His-tagged MrpL35 and Coa3 derivatives
The Yip351-LEU2 vector containing the open reading frame encod-
ing either the wild-type MrpL35 or mrpL35Y275D derivatives or the 
Coa3 protein as C-terminal His12-tagged proteins and downstream 
of the galactose-inducible GAL10 promoter were created. The re-
sulting plasmids were linearized with BstEII and integrated into the 
leu2 loci of indicated yeast strains and LEU+ transformants were se-
lected. The presence of His-tagged derivative proteins in isolated 
mitochondria was confirmed using Western blot approaches with a 
His-specific antibody.
Affinity purification of His-tagged proteins
Isolated mitochondria (200 μg protein) harboring the His-tagged 
protein derivatives were solubilized in lysis buffer (160 mM KCl, 
20 mM HEPES-KOH, 10 mM MgCl2, 0.5 mM phenylmethylsulfonyl 
fluoride [PMSF], pH 7.4), with 1.0% Triton X-100, 0.6% n-dodecyl β-
d-maltoside (DDM), or 1% digitonin, as indicated, for 30 min on ice. 
Following a clarifying spin, Ni-NTA purification of His-tagged pro-
teins was performed as previously described (Jia et al., 2007).
BN–PAGE analysis
BN–PAGE analysis of digitonin (1%) or DDM (0.6%) solubilized mito-
chondrial extracts (30 μg protein) was performed using Invitrogen 
Nu–PAGE gradient (3–12%) gels according to the manufacturer’s 
protocol and followed by Western blotting and antibody decora-
tion, as indicated.
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